Descrizione del progetto
Salvaguardare la salute nel contesto degli effetti metabolici avversi degli interferenti endocrini
Gli interferenti endocrini (IE) rappresentano una minaccia complessa per la salute umana, in quanto colpiscono vie metaboliche fondamentali in organi come il fegato e il pancreas. Questa interferenza è associata all’aumento della prevalenza dell’obesità, dell’aterosclerosi e del diabete di tipo 2, con potenziali effetti a lungo termine che attraversano generazioni. Nonostante queste ripercussioni diffuse, la comprensione degli effetti metabolici degli IE rimane sfuggente ed è ostacolata dalla mancanza di dati meccanicistici e di modelli predittivi. Per colmare questa lacuna, il progetto NEMESIS, finanziato dall’UE, riunisce esperti di varie discipline per svelare i dettagli dell’alterazione metabolica indotta dagli IE tramite diverse metodologie di ricerca e analisi dei dati avanzata. NEMESIS mira a rafforzare le strategie di valutazione dei rischi e a sviluppare pratiche efficaci di comunicazione del rischio per massimizzare le ripercussioni dei risultati del progetto dalla scienza alla politica.
Obiettivo
Endocrine-disrupting chemicals (EDCs) disturb lipid and glucose metabolism in several metabolically active organs such as liver and pancreas besides being able to interfere with many aspects of hormonal action. There is accumulating evidence linking EDCs or their mixtures with an increased incidence of obesity, atherosclerosis, and type 2 diabetes. Developmental exposure to EDCs can exert life-long, even transgenerational effects and affects the susceptibility to many diseases. However, the metabolic effects of EDCs are still poorly understood and the lack of mechanistic data and predictive models of adverse metabolic outcomes of EDCs hinders their risk assessment. The “Novel Effect biomarkers for MEtabolic disruptorS: evidence on health Impacts to science and policy needS” (NEMESIS) consortium brings together experts in toxicology, medicine, risk assessment, and social sciences and humanities to respond to the unmet regulatory needs of EDCs within silico, in vitro, in vivo, epidemiological and systems biology data on EDC-mediated metabolic effects in multifactorial models. We will assess mechanistic data on metabolic disruption in liver and pancreas and how EDCs or their mixtures affect the microbiota, enhanced with data on dose-response relationships and the causality of these actions. In addition, NEMESIS will provide human exposure data of EDCs and explore effect biomarkers for metabolic disruption. NEMESIS’ results will improve assessment of metabolic endpoints in testing guidelines and adopt alternative models to animal testing. Adverse Outcome Pathways (AOP)s and Integrated Approaches to Testing and Assessment (IATA) approaches will be developed to assess adverse metabolic effects of EDCs and improve the risk assessment towards a more holistic approach. Citizens are engaged from the beginning of the project to develop effective risk communication practices on EDCs and to maximize the science-to-policy impact of NEMESIS together with relevant stakeholders.
Campo scientifico
- medical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosis
- medical and health sciencesclinical medicineendocrinologydiabetes
- natural sciencesbiological sciencesbiochemistrybiomoleculeslipids
- medical and health sciencesbasic medicinetoxicology
- medical and health scienceshealth sciencesnutritionobesity
Parole chiave
Programma(i)
Meccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
70211 KUOPIO
Finlandia